Rare - RARE

Ultragenyx Pharmaceutical Bolsa (NASDAQ: RARE)

Ultragenyx Pharmaceutical (NASDAQ:RARE) Bolsa

ULTRAGENYX PHARMACEUTICAL IN

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

<h3>Gainers</h3>
<ul>
<li>Advanced Biomed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVB#NASDAQ">ADVB</a>) stock increased by 11.1% to $0.83 during Friday's after-market session. The company's market cap stands at $16.9 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) stock moved upwards by 7.07% to $6.05. The company's market cap stands at $819.7 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAKA#NASDAQ">NAKA</a>) shares rose 6.12% to $13.0. The company's market cap stands at $100.7 million. </li>
<li>Galectin Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GALT#NASDAQ">GALT</a>) shares increased by 5.97% to $2.66. The market value of their outstanding shares is at $155.0 million. </li>
<li>WORK Medical Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOK#NASDAQ">WOK</a>) stock rose 5.47% to $0.8. The company's market cap stands at $18.9 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock increased by 5.03% to $0.81. The market value of their outstanding shares is at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MiNK Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INKT#NASDAQ">INKT</a>) stock decreased by 18.6% to $52.24 during Friday's after-market session. The company's market cap stands at $30.8 million. </li>
<li>TAO Synergies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOX#NASDAQ">TAOX</a>) stock declined by 16.58% to $7.5. The company's market cap stands at $11.0 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) shares declined by 12.69% to $13.6. The company's market cap stands at $23.7 million. </li>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) shares fell 9.73% to $1.3. The company's market cap stands at $32.7 million. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock fell 9.0% to $19.57. The market value of their outstanding shares is at $313.1 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares fell 8.31% to $27.06. The market value of their outstanding shares is at $2.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADVB

GALT

INKT

NAKA

NGNE

PRPO

RARE

RNTX

TAOX

12 Health Care Stocks Moving In Friday's After-Market Session

Trading Halt: Halt status updated at 4:55:00 PM ET: Quotation Resumption: News and Resumption Times

In the CRL, the FDA requested that the company provide additional information and improvements related to specific aspects of CMC and observations from the recently completed manufacturing facility inspections. The company believes that these observations are readily addressable, related to facilities and processes, and are not directly related to the quality of the product. The company will be working with the FDA over the next few months to resolve the observations. Once resolution is achieved, the company expects to resubmit the BLA and anticipates up to a 6-month review period to follow the resubmission.
Clinical review had been ongoing and the FDA has acknowledged that the neurodevelopmental outcome data provided to date are robust and the biomarker data provide additional supportive evidence. The CRL did not note any review issues related to the clinical data package nor clinical inspections, and asked that updated clinical data from current patients be included in the resubmission.

Biotech

News

General

Ultragenyx Pharmaceutical Expects To Resubmit The BLA And Anticipates Up To A 6-Month Review Period To Follow The Resubmission

Complete Response Letter (CRL) cited specific chemistry, manufacturing and controls (CMC) related observations that are resolvable
FDA clinical reviews acknowledged that the clinical data are robust and&nbsp;biomarker data are supportive
NOVATO, Calif., July 11, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its Biologics License Application (BLA) for UX111 (ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA). s

Ultragenyx Receives FDA Complete Response Letter For UX111 Gene Therapy, Citing Specific Chemistry, Manufacturing And Controls Related Observations That Are Resolvable

Trading Halt: Halted at 4:25:00 p.m. ET - Trading Halt: Halt News Pending

Ratings for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $64.75, a high estimate of $65.00, and a low estimate of $64.00. This current average has decreased by 10.07% from the previous average price target of $72.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752184856_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of Ultragenyx Pharmaceutical by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Sami Corwin</td>
<td>William Blair</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ultragenyx Pharmaceutical. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ultragenyx Pharmaceutical's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Ultragenyx Pharmaceutical</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Ultragenyx Pharmaceutical: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Ultragenyx Pharmaceutical's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 27.99% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Ultragenyx Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -108.46% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -75.63%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -10.73%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio stands notably higher than the industry average, reaching 0.27. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Ultragenyx Pharmaceutical: 4 Analysts Share Their Views

Financial giants have made a conspicuous bearish move on Ultragenyx Pharmaceutical. Our analysis of options history for Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) revealed 10 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 60% showed bearish tendencies. Out of all the trades we spotted, 6 were puts, with a value of $276,249, and 4 were calls, valued at $290,790.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.5 to $40.0 for Ultragenyx Pharmaceutical over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Ultragenyx Pharmaceutical's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Ultragenyx Pharmaceutical's significant trades, within a strike price range of $22.5 to $40.0, over the past month.
<h3>Ultragenyx Pharmaceutical Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752170460_0_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$2.15</td>
<td>$1.65</td>
<td>$2.1</td>
<td>$40.00</td>
<td>$159.3K</td>
<td>1.0K</td>
<td>1.0K</td>
</tr>
<tr>
<td>RARE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$4.9</td>
<td>$4.8</td>
<td>$4.8</td>
<td>$35.00</td>
<td>$74.4K</td>
<td>38</td>
<td>0</td>
</tr>
<tr>
<td>RARE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$3.5</td>
<td>$2.1</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$64.0K</td>
<td>0</td>
<td>250</td>
</tr>
<tr>
<td>RARE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.8</td>
<td>$3.0</td>
<td>$4.7</td>
<td>$35.00</td>
<td>$47.0K</td>
<td>1.6K</td>
<td>652</td>
</tr>
<tr>
<td>RARE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.8</td>
<td>$2.85</td>
<td>$4.7</td>
<td>$35.00</td>
<td>$47.0K</td>
<td>1.6K</td>
<td>452</td>
</tr>
</tbody>
</table>

<h3>About Ultragenyx Pharmaceutical</h3>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Following our analysis of the options activities associated with Ultragenyx Pharmaceutical, we pivot to a closer look at the company's own performance.
<h3>Current Position of Ultragenyx Pharmaceutical</h3>
<ul>
<li>With a volume of 9,702,498, the price of RARE is down -19.86% at $33.21. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 21 days.</li>
</ul>
<h3>What The Experts Say On Ultragenyx Pharmaceutical</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $64.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for Ultragenyx Pharmaceutical, targeting a price of $65. 
&#x2A; In a cautious move, an analyst from Guggenheim downgraded its rating to Buy, setting a price target of $64. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Ultragenyx Pharmaceutical, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

Ultragenyx Pharmaceutical's Options: A Look at What the Big Money is Thinking

<h3>Gainers</h3>
<ul>
<li>Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) shares moved upwards by 52.3% to $2.3 during Thursday's regular session. The company's market cap stands at $18.4 million. </li>
<li>Pelthos Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTHS#AMEX">PTHS</a>) shares moved upwards by 52.09% to $25.05. The company's market cap stands at $10.6 million. </li>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) stock increased by 39.28% to $0.74. The market value of their outstanding shares is at $32.9 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 28.9% to $0.9. The company's market cap stands at $22.2 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares increased by 28.54% to $3.54. The company's market cap stands at $7.5 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) shares moved upwards by 23.96% to $5.38. The company's market cap stands at $562.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares decreased by 38.8% to $1.8 during Thursday's regular session. The market value of their outstanding shares is at $467.4 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) stock fell 27.42% to $30.08. The company's market cap stands at $3.9 billion. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock decreased by 22.21% to $3.06. The company's market cap stands at $10.1 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) shares decreased by 21.25% to $4.69. The market value of their outstanding shares is at $113.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 19.13% to $3.51. The company's market cap stands at $310.5 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares decreased by 16.8% to $3.01. The market value of their outstanding shares is at $68.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BMGL

CELZ

CGTX

CLDI

CTOR

LIXT

MREO

NTHI

PROK

PTHS

QTTB

12 Health Care Stocks Moving In Thursday's Intraday Session

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday.
The Dow traded up 0.52% to 44,690.50 while the NASDAQ declined 0.03% to 20,605.11. The S&amp;P 500 also rose, gaining, 0.23% to 6,278.25.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Health care shares jumped by 1.2% on Thursday.
In trading on Thursday, communication services stocks dipped by 1%.
Top Headline
Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) posted stronger-than-expected second-quarter results and reinstated its full-year 2025 guidance.
Operating revenue for the quarter was $16.65 billion, flat from a year ago but above the consensus estimate of $16.18 billion. Adjusted operating revenue rose 1% year over year to $15.51 billion.
Adjusted earnings per share were $2.10, down 11% from the year-ago period but topping expectations of $2.05. The airline's adjusted average fuel price fell to $2.26 per gallon, compared with $2.64 last year.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares shot up 425% to $1.87 on continued strength following its merger agreement with Palm Global on Monday.</li>
<li>Shares of DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) got a boost, surging 217% to $13.51 after the company announced Hearst will acquire it for $14 per share.</li>
<li>BIT Mining Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NASDAQ">BTCM</a>) shares were also up, gaining 111% to $5.20 after the company announced it plans an investment up to $300 million to expand into the Solana ecosystem.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares dropped 33% to $1.9600. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were down 27% to $30.45. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) was down, falling 30% to $1.4250 as the company announced the pricing of $60 million underwritten public offering at a price of $5/share.</li>
</ul>
Commodities In commodity news, oil traded down 2.3% to $66.79 while gold traded up 0.2% at $3,326.70.
Silver traded up 1.2% to $37.075 on Thursday, while copper rose 2.3% to $5.6115.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.49%, while Spain's IBEX 35 Index fell 0.70%. London's FTSE 100 gained 1.21%, Germany's DAX 40 slipped 0.36% and France's CAC 40 gained 0.22% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.44%, Hong Kong's Hang Seng gaining 0.57%, China's Shanghai Composite gaining 0.48% and India's BSE Sensex falling 0.41%.
Economics
<ul class="wp-block-list">
<li>U.S. initial jobless claims declined by 5,000 from the previous week to 227,000 in the first week of July, compared to market estimates of 235,000.</li>
<li>U.S. natural gas stocks rose 53 billion cubic feet for the week ended July 4.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46341009/how-to-earn-500-a-month-from-jpmorgan-stock-ahead-of-q2-earnings">How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

ABVE

BTCM

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings

Wells Fargo analyst Tiago Fauth maintains Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Overweight and lowers the price target from $88 to $65.

Price Target

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $65

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday.
Following the market opening Thursday, the Dow traded up 0.24% to 44,564.14 while the NASDAQ declined 0.44% to 20,520.54. The S&amp;P 500 also fell, dropping, 0.09% to 6,257.81.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46318208/top-2-tech-stocks-that-may-plunge-this-month">Top 2 Tech Stocks That May Plunge This Month</a>
Leading and Lagging Sectors Health care shares jumped by 0.9% on Thursday.
In trading on Thursday, communication services stocks dipped by 1.2%.
Top Headline
U.S. initial jobless claims declined by 5,000 from the previous week to 227,000 in the first week of July, compared to market estimates of 235,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) shares shot up 330% to $1.53 on continued strength following its merger agreement with Palm Global on Monday.</li>
<li>Shares of DallasNews Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DALN#NASDAQ">DALN</a>) got a boost, surging 218% to $13.55 after the company announced Hearst will acquire it for $14 per share.</li>
<li>BIT Mining Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCM#NASDAQ">BTCM</a>) shares were also up, gaining 117% to $5.34 after the company announced it plans an investment up to $300 million to expand into the Solana ecosystem.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares dropped 35% to $1.9150. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) were down 27% to $30.11. Ultragenyx Pharmaceutical and Mereo BioPharma on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent with the original plan.</li>
<li>CURRENC Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) was down, falling 27% to $1.48 as the company announced the pricing of $60 million underwritten public offering at a price of $5/share.</li>
</ul>
Commodities In commodity news, oil traded down 1.8% to $67.14 while gold traded up 0.1% at $3,322.90.
Silver traded up 0.8% to $36.930 on Thursday, while copper rose 1.8% to $5.5885.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 rose 0.5%, while Spain's IBEX 35 Index fell 0.6%. London's FTSE 100 gained 1.1%, Germany's DAX 40 slipped 0.3% and France's CAC 40 gained 0.3% during the session.
Asia Pacific Markets
Asian markets closed mixed on Thursday, with Japan's Nikkei falling 0.44%, Hong Kong's Hang Seng gaining 0.57%, China's Shanghai Composite gaining 0.48% and India's BSE Sensex falling 0.41%.
Economics
U.S. initial jobless claims declined by 5,000 from the previous week to 227,000 in the first week of July, compared to market estimates of 235,000.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46341009/how-to-earn-500-a-month-from-jpmorgan-stock-ahead-of-q2-earnings">How To Earn $500 A Month From JPMorgan Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

US Stocks Mixed; Initial Jobless Claims Fall

Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) and Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) stocks are plunging on Thursday.
<h2 class="wp-block-heading">What Happened?</h2>
The companies on Wednesday announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis around the end of the year, consistent <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/g46331268/ultragenyx-and-mereo-biopharma-announce-ux143-phase-3-orbit-study-for-osteogenesis-imperfecta-prog" rel="noreferrer noopener">with the original plan</a>.
OI, also known as <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">brittle bone disease</a>, is a group of genetic disorders that make bones abnormally fragile and prone to fractures.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45655477/analyst-bullish-on-ultragenyx-poised-for-growth-with-six-drug-approvals-expected-by-2028" rel="noreferrer noopener">Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028</a>
William Blair noted that the update implies the second interim analysis did not meet the minimal p-value threshold of p&lt;0.01 to end the study early.
The Data Monitoring Committee (DMC) met and informed the company that UX143 demonstrates an acceptable safety profile, and the company should continue the study to the final analysis.
&#8220;While we had hoped to be able to stop the study early, we look forward to having results from both Orbit and Cosmic around the end of this year,&#8221; said Emil Kakkis, chief executive officer and president of Ultragenyx.
Consistent with the statistical analysis plan, data from the Cosmic study were not analyzed at this interim time point. The study is going well, and safety in this younger patient population is consistent with the safety profile of the other studies.
Patients will continue dosing in the ongoing Phase 3 Orbit and Cosmic clinical studies. The final analyses will be conducted after patients have been on therapy for at least 18 months.
The threshold for the Phase 3 Orbit final analysis is p&lt;0.04, and for the Phase 3 Cosmic final analysis is p&lt;0.05.
<h2 class="wp-block-heading">Analyst&#8217;s Take</h2>
William Blair acknowledged the disappointment that the Orbit study didn&#8217;t achieve statistical significance at the second interim analysis. However, they believe the market&#8217;s reaction is severely overdone. They anticipate a high likelihood of a positive outcome from the final analysis in the fourth quarter, citing the longer follow-up duration and a lower statistical significance threshold.
Analyst Sami Corwin from William Blair reiterated, &#8220;We continue to believe that the Phase II Orbit data support setrusumab as a clinically active molecule in OI, and we do not think this update impacts the top-line analyses&#8217; probability of success.&#8221;
Price Action: RARE stock is trading lower by 26.2% to $30.60, and MREO stock is down 34.7% at $1.919 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46342110/amazon-unveils-powerful-new-ai-servers-to-support-nvidias-most-advanced-chips" target="_blank" rel="noreferrer noopener">Amazon Unveils Powerful New AI Servers To Support Nvidia&#8217;s Most Advanced Chips</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Health Care

Ultragenyx, Mereo Shares Dive As Brittle Bone Disease Drug Misses Early Win

<h3>Gainers</h3>
<ul>
<li>Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) shares rose 45.7% to $0.78 during Thursday's pre-market session. The market value of their outstanding shares is at $32.9 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 22.62% to $1.68. The market value of their outstanding shares is at $49.9 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) stock rose 21.91% to $0.45. The market value of their outstanding shares is at $29.1 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock moved upwards by 17.97% to $5.12. The market value of their outstanding shares is at $562.1 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock rose 16.94% to $15.41. The company's market cap stands at $1.0 billion. The company's, Q2 earnings came out yesterday. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares moved upwards by 16.47% to $6.08. The market value of their outstanding shares is at $135.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares decreased by 31.0% to $2.03 during Thursday's pre-market session. The company's market cap stands at $467.4 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares fell 26.91% to $2.88. The market value of their outstanding shares is at $10.1 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) stock decreased by 20.37% to $33.0. The company's market cap stands at $3.9 billion. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares declined by 18.79% to $2.94. The market value of their outstanding shares is at $68.0 million. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock declined by 18.37% to $0.36. The market value of their outstanding shares is at $27.4 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock fell 16.6% to $1.21. The market value of their outstanding shares is at $2.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEMD

KLTO

LIMN

NRIX

PASG

12 Health Care Stocks Moving In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Thursday.
Shares of Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell sharply in today's pre-market trading after the company reported a fourth-quarter <a href="https://www.benzinga.com/quote/MEI">adjusted EPS miss</a>.
Methode Electronics posted adjusted loss of 77 cents per share, missing market estimates of earnings of 4 cents per share, according to data from Benzinga Pro. The company' sales came in at $257.10 million versus estimates of $232.87 million.
Methode Electronics shares jumped 15.1% to $8.74 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares tumbled 36.6% to $1.87 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) dipped 21.3% to $32.50 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) fell 11% to $1.79 in pre-market trading after dipping 20% on Wednesday.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) shares fell 10.5% to $5.89 in pre-market trading after gaining over 56% on Wednesday.</li>
<li>Altimmune, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) dipped 8.4% to $4.34 in pre-market trading. Altimmune on Wednesday initiated RESTORE Phase 2 trial evaluating efficacy and safety of pemvidutide for alcohol-associated liver disease.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 7.7% to $61.60 in pre-market trading. BitMine Immersion Technologies shares dipped 40% on Wednesday after the company filed for a mixed shelf.</li>
<li>Hotel101 Global Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBNB#NASDAQ">HBNB</a>) dipped 5.3% to $3.42 in after-hours trading session.</li>
<li>Metsera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) fell 4.3% to $33.80 in pre-market trading after gaining 17% on Wednesday.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

BMNR

HBNB

MTSR

SCAG

WOLF

Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Shares of WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) rose sharply in today's pre-market trading following a WSJ report <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46332395/wk-kellogg-stock-pops-50-on-potential-3-billion-acquisition">suggesting Ferrero is nearing a deal to acquire the company.</a>
Family-owned Italian candy company Ferrero is closing in on a deal to acquire cereal maker WK Kellogg for roughly $3 billion, according to a Wall Street Journal report. People familiar with the matter reportedly said a deal could be completed as soon as this week.
WK Kellogg shares jumped 50.2% to $26.31 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Steakholder Foods Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKH#NASDAQ">STKH</a>) surged 137.6% to $4.16 in pre-market trading.</li>
<li>GIBO Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) climbed 51.4% to $0.0512 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Nurix Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) rose 51.1% to $20.00 in pre-market trading as the company posted better-than-expected second-quarter results.</li>
<li>IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) jumped 51.1% to $0.5550 in pre-market trading after gaining 15% on Wednesday. IGC Pharma has been making significant strides in its field. In June, the company highlighted its fiscal year 2025 with clinical progress and Alzheimer's drug development advances. This included the presentation of a scientific poster titled "Genetic Toxicity Evaluation Of Melatonin In The Bacterial Reverse Mutation Assay," at the 2025 Genetic Toxicology Association Annual Meeting.</li>
<li>Klotho Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) gained 43.1% to $1.96 in pre-market trading as the company was granted FDA Orphan Drug designation for KLTO-202 for the treatment of amyotrophic lateral sclerosis. </li>
<li>NuCana plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) gained 37.4% to $0.0831 in pre-market trading after gaining 8% on Wednesday.</li>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 29.4% to $0.9000 in pre-market trading. Pop Culture Group, a China-based company focused on developing and hosting hip-hop and other entertainment events, completed a private placement on July 4, 2025.</li>
<li>POET Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POET#NASDAQ">POET</a>) gained 15% to $7.01 in pre-market trading after climbing 18% on Wednesday.</li>
<li>ProKidney Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) gained 13.8% to $4.94 in pre-market trading as investors continue to cheer statistically significant and clinically meaningful results from its Phase 2 REGEN-007 trial for rilparencel.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) dipped 36.6% to $1.87 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Creative Medical Technology Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares tumbled 25.3% to $2.93 in pre-market trading. Creative Medical Technology has received a notice of allowance for a U.S. patent titled &#8220;Treatment Of Heart Failure And/Or Post Infarct Pathological Remodeling By Ex Vivo Reprogrammed Immune Cells.&#8221;</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 21.3% to $32.50 in pre-market trading. Ultragenyx and Mereo BioPharma announced UX143 Phase 3 orbit study for osteogenesis imperfecta progressing to final analysis.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) dipped 17.2% to $3.00 in pre-market trading after gaining 99% on Wednesday.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) fell 15.1% to $8.74 in pre-market trading after the company reported a fourth-quarter adjusted EPS miss.</li>
<li>Aethlon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) fell 13.2% to $1.26 in pre-market trading.</li>
<li>Delixy Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLXY#NASDAQ">DLXY</a>) declined 11.4% to $4.38 in pre-market trading after gaining 24% on Wednesday.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) declined 11% to $1.79 in pre-market trading after dipping 20% on Wednesday.</li>
<li>Scage Future (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCAG#NASDAQ">SCAG</a>) shares fell 10.5% to $5.89 in pre-market trading after gaining over 56% on Wednesday.</li>
<li>Bitmine Immersion Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#NYSE">BMNR</a>) fell 7.7% to $61.60 in pre-market trading. BitMine Immersion Technologies shares dipped 40% on Wednesday after the company filed for a mixed shelf.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Photo via Shutterstock

CPOP

DLXY

GIBO

NCNA

POET

STKH

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares moved upwards by 56.4% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $25.3 million. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) stock moved upwards by 11.03% to $7.95. The market value of their outstanding shares is at $580.9 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares increased by 10.93% to $0.34. The market value of their outstanding shares is at $7.5 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) stock increased by 9.35% to $5.73. The market value of their outstanding shares is at $163.3 million. </li>
<li>Nurix Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) stock moved upwards by 7.73% to $14.2. The company's market cap stands at $930.8 million. The company's, Q2 earnings came out today. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 6.95% to $1.23. The company's market cap stands at $2.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mereo BioPharma Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>) shares fell 37.7% to $1.83 during Wednesday's after-market session. The market value of their outstanding shares is at $449.9 million. </li>
<li>Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) shares fell 27.66% to $29.98. The market value of their outstanding shares is at $3.7 billion. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) shares declined by 27.33% to $2.86. The company's market cap stands at $6.9 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) stock declined by 9.95% to $3.26. The market value of their outstanding shares is at $34.1 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) shares fell 7.59% to $1.34. The market value of their outstanding shares is at $2.3 million. </li>
<li>Jin Medical International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares fell 6.73% to $0.55. The company's market cap stands at $90.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTS

PSNL

ZJYL

12 Health Care Stocks Moving In Wednesday's After-Market Session

Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) and Mereo BioPharma Group plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MREO#NASDAQ">MREO</a>), today announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis consistent with the original plan, around the end of the year.
The Data Monitoring Committee (DMC) met and informed the company that UX143 demonstrates an acceptable safety profile and the company should continue the study to the final analysis.

Ultragenyx And Mereo BioPharma To Complete Phase 3 UX143 Trials In Osteogenesis Imperfecta By Year-End; Data Monitoring Committee Supports Continued Study With Safety Profile

Ultragenyx Receives FDA Breakthrough Therapy Designation For GTX-102 In Angelman Syndrome

4 analysts have expressed a variety of opinions on Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $77.75, a high estimate of $117.00, and a low estimate of $64.00. This current average reflects an increase of 0.54% from the previous average price target of $77.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1750428056_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Ultragenyx Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$64.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Sami Corwin</td>
<td>William Blair</td>
<td>Announces</td>
<td>Outperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Ultragenyx Pharmaceutical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Ultragenyx Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Ultragenyx Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Ultragenyx Pharmaceutical's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RARE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ultragenyx Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Ultragenyx Pharmaceutical</h2>
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
<h3>Breaking Down Ultragenyx Pharmaceutical's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Ultragenyx Pharmaceutical's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 27.99%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Ultragenyx Pharmaceutical's net margin is impressive, surpassing industry averages. With a net margin of -108.46%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Ultragenyx Pharmaceutical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -75.63%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Ultragenyx Pharmaceutical's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -10.73%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Ultragenyx Pharmaceutical's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.27, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Ultragenyx Pharmaceutical Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Guggenheim analyst Debjit Chattopadhyay reiterates Ultragenyx Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) with a Buy and maintains $64 price target.

Reiteration

Guggenheim Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $64 Price Target

Press Releases

Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis

Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Comments

Ultragenyx Pharmaceutical

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL